Vantage Financial Partners Ltd. Inc. Raises Position in Johnson & Johnson (NYSE:JNJ)

Vantage Financial Partners Ltd. Inc. lifted its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 3.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,280 shares of the company’s stock after buying an additional 575 shares during the period. Johnson & Johnson makes up 1.6% of Vantage Financial Partners Ltd. Inc.’s portfolio, making the stock its 13th biggest position. Vantage Financial Partners Ltd. Inc.’s holdings in Johnson & Johnson were worth $2,712,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of JNJ. American Financial Advisors LLC raised its holdings in shares of Johnson & Johnson by 2.1% during the first quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock worth $481,000 after acquiring an additional 57 shares in the last quarter. Taylor & Morgan Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 1.6% during the second quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock worth $635,000 after acquiring an additional 57 shares in the last quarter. Circle Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 0.5% during the first quarter. Circle Wealth Management LLC now owns 11,326 shares of the company’s stock worth $2,007,000 after acquiring an additional 59 shares in the last quarter. Argus Investors Counsel Inc. raised its holdings in shares of Johnson & Johnson by 0.6% during the second quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock worth $1,941,000 after acquiring an additional 61 shares in the last quarter. Finally, Alta Capital Management LLC raised its holdings in shares of Johnson & Johnson by 0.4% during the second quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock worth $2,808,000 after acquiring an additional 61 shares in the last quarter. Hedge funds and other institutional investors own 68.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on JNJ shares. UBS Group cut their target price on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Morgan Stanley cut their target price on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 19th. Barclays started coverage on Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price on the stock. Citigroup cut their target price on Johnson & Johnson from $201.00 to $198.00 in a report on Wednesday, October 5th. Finally, Bank of America dropped their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research note on Friday, October 14th. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $184.25.

Johnson & Johnson Stock Down 3.0 %

JNJ stock opened at $169.25 on Friday. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a market cap of $442.50 billion, a PE ratio of 23.57, a price-to-earnings-growth ratio of 3.42 and a beta of 0.57. The business’s 50-day simple moving average is $166.88 and its 200 day simple moving average is $171.59. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The business had revenue of $23.79 billion for the quarter, compared to the consensus estimate of $23.44 billion. During the same period last year, the business earned $2.60 earnings per share. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.67%. The ex-dividend date of this dividend is Monday, November 21st. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Johnson & Johnson declared that its Board of Directors has approved a stock repurchase program on Wednesday, September 14th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 1.2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Peter Fasolo sold 22,864 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the sale, the vice president now directly owns 114,676 shares in the company, valued at $18,864,202. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 118,795 shares of company stock valued at $20,230,174. 0.35% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.